Concino Bio today landed on the board to become the first "A-H" vaccine unit.

On August 13th, Concino Bio AG ("Consino Bio") successfully landed on the board, becoming the first "A-H" vaccine unit.
24.8 million shares, with an issue price of 209.71 yuan.
that the funds raised will be used for the second phase of production base construction, vaccine research and development, vaccine traceability, cold chain logistics system and information system construction and supplementary working capital. Dr. Yu Xuefeng, Chairman and CEO of
Consino Bio, said: "The launch of the Shanghai Stock Exchange and the reform of the listing system of the Hong Kong Stock Exchange are extremely important policy support for biopharmaceutical enterprises that have invested large-scale and long cycles in the early stages and need to continue to obtain funds to promote research and development, and are of positive significance for the promotion of corporate brand value and the strategic layout of globalization based on China."
" Concino Bio, with the goal of providing solutions to prevent infectious diseases and infections worldwide, specializes in the research and development, production and commercialization of high-quality human vaccines, and under the leadership of a large number of well-known scientists and senior technical experts in the field of vaccines, has established four core technology platforms, such as adenovirus vector vaccine technology, protein structure design and recombination technology, combination technology and preparation technology, with a number of vaccine core intellectual property rights and know-how.
Relying on the above-mentioned technology platform, Concino Bio has developed 16 heavy vaccines for 13 adaptations such as meningitis, Ebola virus disease, white-shave, pneumonia, tuberculosis, new coronavirus (COVID-19), shingles, etc., and has rapidly advanced the development of pipeline products in the study.
Among them, the recombinant Ebola virus disease vaccine (adenovirus vector) developed in cooperation with the Institute of Bioengineering of the Institute of Military Medicine of the Concino Institute of Biological and Military Sciences (hereinafter referred to as the Institute of Bioengineering of the Academy of Military Sciences) has been approved for the registration of new drugs, and is an innovative global vaccine product developed independently in China with fully independent intellectual property rights.
two meningococcal-binding vaccines in the study are nearing commercialization, and the country's first four-price meningococcal-binding vaccine has been approved as a priority for the registration of new drugs by the State Drug Administration.
In March 2020, the recombinant new coronavirus vaccine (adenovirus vector) jointly developed by the Institute of Bioengineering of the Concino Institute of Biological Sciences and the Academy of Military Sciences became the world's first new crown candidate vaccine to enter the clinical research phase.
In addition, Consino Bio's recombinant pneumonia protein vaccine, 13-price pneumococcal binding vaccine, infant and young child group 100 white-crack vaccine, tuberculosis enhanced vaccine and other innovative vaccines are in clinical trials, and six candidate vaccines are in the preclinical research phase.
.